A Phase 4 interventional study of Paliperidone ER and Oral risperidone in Schizophrenia, sponsored by Janssen-Cilag G.m.b.H. Terminated at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-02-11.
Sponsored by Janssen-Cilag G.m.b.H (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.
Among the 115 studies testing paliperidone in Schizophrenia, this one is the 113th largest by enrollment, is one of 11 that started in 2009, is one of 42 in phase 4, and was the 48th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Alejandro Alva · Sites in United States
Ages 18–65
Jiangsu Province Nanjing Brain Hospital · Sites in China
Ages 18–65
Sher-E-Bangla Medical College · Sites in Bangladesh
Ages 18–60
By country, each count listing its studies:
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 7 · Phase 3 42 · Phase 4 42
First in 2003; this study’s year is marked. 11 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 115 interventional studies. Of the 104 that completed or were terminated, 42 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen-Cilag G.m.b.H, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag G.m.b.H is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 174th largest by enrollment of the 176 interventional ones that give a count, is one of 13 that started in 2009, is one of 47 in phase 4, and was the 123rd registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing paliperidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies testing paliperidone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to compare the effect of two different antipsychotic compounds which are used in the treatment of schizophrenia (paliperidone ER and risperidone) at their target sites in two specific areas of the brain in patients with schizophrenia. A specialized X-ray known as Positron Emission Tomography (PET) Imaging is used to assess the areas of the brain targeted by both compounds.
This is an open-label (all people involved know the identity of the intervention), non-randomized (patients are assigned to treatment groups), phase IV, monocentric (at one single study site) interventional study evaluating the blocking effects two different doses of paliperidone ER and oral risperidone have on the dopamine D2 receptors in the brain of subchronic patients with schizophrenia. Dopamine is a substance produced and released in the brain. Research indicates that dopamine levels are elevated in some areas of the brain in acute schizophrenia psychosis. Antipsychotic medications like risperidone and paliperidone ER are used to treat psychosis by blocking the dopamine receptors. Fallypride is a radioactive tracer (a drug that emits radioactivity) that binds to the dopamine receptors in the brain much the same as antipsychotic medications. It competes with the antipsychotic compounds at the binding sites and is used when performing a specialized x-ray known as Positron Emission Tomography (PET) Imaging. After a patient receives Fallypride, it temporally binds to specific target areas in the brain and emits a brief and harmless radioactive signal that is detected by the PET Scanner. Since paliperidone ER and risperidone compete with Fallypride at the same target sites, the signal will differ according to the binding effect of the compound. This technique provides an image showing the direct effect medication has on the human brain and allows for comparisons of the effects of different medications to be made. As this effect will fluctuate depending on the concentration of the drug in the blood, during this study, PET measurements will be correlated with the blood levels sampled. Patients will receive either paliperidone ER (6 patients with 6 mg per day, 6 patients with 9 mg per day) or oral risperidone (6 patients with 4 mg per day, 6 patients with 6 mg per day). The primary objective of this study is to compare the blocking effects each medication has on the dopamine D2 receptors at different time points (shortly after taking medication and 24 hours after taking medication) correlated with blood levels of the medication. The study consists of 3 visits on 3 consecutive days. Blood levels will be assessed for treatment groups 1 to 4 on day 2 and day 3 and for groups 5 to 8 on day 3 (according to the last intake of study medication). PET-Scans will be assessed for every group on day 3. Group 1 to 4 consists of patients whose PET Scan will be assessed approximately 2 hours after taking medication (group 1 receives paliperidone ER 6 mg, group 2 receives paliperidone ER 9 mg, group 3 receives risperidone 4 mg, group 4 receives risperidone 6 mg). Group 5 to 8 consists of patients whose PET Scan will be assessed approximately 24 hours after taking medication (group 5 receives paliperidone ER 6 mg, group 6 receives paliperidone ER 9 mg, group 7 receives risperidone 4 mg, group 8 receives risperidone 6 mg). Adverse Events (AE's) will be assessed as reported spontaneously throughout the trial. The dose of antipsychotic medication will represent the most frequent dose used in post acute treatment of schizophrenia. A group of healthy volunteers (group 9) will serve as a control group to measure fallypride dopamine D2- receptor occupancies under normal circumstances, in patients not affected by schizophrenia. Patients will receive the same dosage throughout the study as prescribed prior to the start of the study either paliperidone ER 6 mg tablet once daily or 9 mg tablet once daily or risperidone 4 mg tablet once daily or 6 mg daily (two 3 mg tablets).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 2 hours
Drug: Paliperidone ER
Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 2 hours
Drug: Oral risperidone
Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 2 hours
Drug: Oral risperidone
Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 24 hours
Drug: Paliperidone ER
Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 24 hours
Drug: Paliperidone ER
Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 24 hours
Drug: Oral risperidone
Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 24 hours
Drug: Oral risperidone
PET Scan PET Scan
Other: PET Scan
Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 2 hours
Drug: Paliperidone ER
9 mg tablet once a day followed by PET scan in approximately 2 hours
6 mg tablet once a day followed by PET scan in approximately 2 hours
PET Scan
4 mg tablet once a day followed by PET scan in approximately 24 hours
4 mg tablet once a day followed by PET scan in approximately 2 hours
6 mg tablet once a day followed by PET scan in approximately 2 hours
6 mg tablet once a day followed by PET scan in approximately 24 hours
6 mg tablet once a day followed by PET scan in approximately 24 hours
9 mg tablet once a day followed by PET scan in approximately 24 hours
Percentage of Paliperidone or Risperidone Dopamine D2 Receptor Occupancies
Time frame: Visit 3 (on day 3)
Plasma Concentrations of Paliperidone and Risperidone
No measures available due to early termination of trial
Time frame: Measurement of plasma concentration at Visit 3 (day 3)
Assessment of the Ratio of Dopamine D2-receptor Occupancies in Two Different Areas of the Brain
No measures available due to early termination of trial
Time frame: Analysis of PET scans at Visit 3 (day 3)
| Milestone | Paliperidone ER 6 mg Tablet Followed by PET Scan in 2 Hours | Paliperidone ER 9 mg Tablet Followed by PET Scan in 2 Hours | Oral Risperidone 4 mg Tablet Followed by PET Scan in 2 Hours | Oral Risperidone 6 mg Tablet Followed by PET Scan in 2 Hours | Paliperidone ER 6 mg Tablet Followed by PET Scan in 24 Hours | Paliperidone ER 9 mg Tablet Followed by PET Scan in 24 Hours | Oral Risperidone 4 mg Tablet Followed by PET Scan in 24 Hours | Oral Risperidone 6 mg Tablet Followed by PET Scan in 24 Hours | Control |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Completed | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| percentage | Paliperidone ER 6 mg Tablet Followed by PET Scan in 2 Hours | Paliperidone ER 9 mg Tablet Followed by PET Scan in 2 Hours | Oral Risperidone 4 mg Tablet Followed by PET Scan in 2 Hours | Oral Risperidone 6 mg Tablet Followed by PET Scan in 2 Hours | Paliperidone ER 6 mg Tablet Followed by PET Scan in 24 Hours | Paliperidone ER 9 mg Tablet Followed by PET Scan in 24 Hours | Oral Risperidone 4 mg Tablet Followed by PET Scan in 24 Hours | Oral Risperidone 6 mg Tablet Followed by PET Scan in 24 Hours | Control |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Paliperidone or Risperidone Dopamine D2 Receptor Occupancies | — | 0 | — | — | — | — | — | — | 0 |
No measures available due to early termination of trial
Results for this outcome have not been posted.
No measures available due to early termination of trial
Results for this outcome have not been posted.
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paliperidone ER 6 mg Tablet Followed by PET Scan in 2 Hours | — | — | — |
| Paliperidone ER 9 mg Tablet Followed by PET Scan in 2 Hours | — | 1/1 (100%) | 0/1 (0%) |
| Oral Risperidone 4 mg Tablet Followed by PET Scan in 2 Hours | — | — | — |
| Oral Risperidone 6 mg Tablet Followed by PET Scan in 2 Hours | — | — | — |
| Paliperidone ER 6 mg Tablet Followed by PET Scan in 24 Hours | — | — | — |
| Paliperidone ER 9 mg Tablet Followed by PET Scan in 24 Hours | — | — | — |
| Oral Risperidone 4 mg Tablet Followed by PET Scan in 24 Hours | — | — | — |
| Oral Risperidone 6 mg Tablet Followed by PET Scan in 24 Hours | — | — | — |
| Control | — | 0/1 (0%) | 0/1 (0%) |
| Event | Paliperidone ER 6 mg Tablet Followed by PET Scan in 2 Hours | Paliperidone ER 9 mg Tablet Followed by PET Scan in 2 Hours | Oral Risperidone 4 mg Tablet Followed by PET Scan in 2 Hours | Oral Risperidone 6 mg Tablet Followed by PET Scan in 2 Hours | Paliperidone ER 6 mg Tablet Followed by PET Scan in 24 Hours | Paliperidone ER 9 mg Tablet Followed by PET Scan in 24 Hours | Oral Risperidone 4 mg Tablet Followed by PET Scan in 24 Hours | Oral Risperidone 6 mg Tablet Followed by PET Scan in 24 Hours | Control |
|---|---|---|---|---|---|---|---|---|---|
| Exacerbation of schizophrenic symptomsPsychiatric disorders | — | 1/1 | — | — | — | — | — | — | 0/1 |
| Age, Categorical(participants) | Paliperidone ER 6 mg Tablet Followed by PET Scan in 2 Hours | Paliperidone ER 9 mg Tablet Followed by PET Scan in 2 Hours | Oral Risperidone 4 mg Tablet Followed by PET Scan in 2 Hours | Oral Risperidone 6 mg Tablet Followed by PET Scan in 2 Hours | Paliperidone ER 6 mg Tablet Followed by PET Scan in 24 Hours | Paliperidone ER 9 mg Tablet Followed by PET Scan in 24 Hours | Oral Risperidone 4 mg Tablet Followed by PET Scan in 24 Hours | Oral Risperidone 6 mg Tablet Followed by PET Scan in 24 Hours | Control | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | — | 0 | — | — | — | — | — | — | 0 | 0 |
| Between 18 and 65 years | — | 1 | — | — | — | — | — | — | 1 | 2 |
| >=65 years | — | 0 | — | — | — | — | — | — | 0 | 0 |
| Age, Customized(years) | Paliperidone ER 6 mg Tablet Followed by PET Scan in 2 Hours | Paliperidone ER 9 mg Tablet Followed by PET Scan in 2 Hours | Oral Risperidone 4 mg Tablet Followed by PET Scan in 2 Hours | Oral Risperidone 6 mg Tablet Followed by PET Scan in 2 Hours | Paliperidone ER 6 mg Tablet Followed by PET Scan in 24 Hours | Paliperidone ER 9 mg Tablet Followed by PET Scan in 24 Hours | Oral Risperidone 4 mg Tablet Followed by PET Scan in 24 Hours | Oral Risperidone 6 mg Tablet Followed by PET Scan in 24 Hours | Control | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| 27 years of age | — | 1 ± NA | — | — | — | — | — | — | 0 ± NA | 1 |
| 19 years of age | — | 0 | — | — | — | — | — | — | 1 | 1 |
| Gender(participants) | Paliperidone ER 6 mg Tablet Followed by PET Scan in 2 Hours | Paliperidone ER 9 mg Tablet Followed by PET Scan in 2 Hours | Oral Risperidone 4 mg Tablet Followed by PET Scan in 2 Hours | Oral Risperidone 6 mg Tablet Followed by PET Scan in 2 Hours | Paliperidone ER 6 mg Tablet Followed by PET Scan in 24 Hours | Paliperidone ER 9 mg Tablet Followed by PET Scan in 24 Hours | Oral Risperidone 4 mg Tablet Followed by PET Scan in 24 Hours | Oral Risperidone 6 mg Tablet Followed by PET Scan in 24 Hours | Control | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | — | 0 | — | — | — | — | — | — | 1 | 1 |
| Male | — | 1 | — | — | — | — | — | — | 0 | 1 |
| Region of Enrollment(participants) | Paliperidone ER 6 mg Tablet Followed by PET Scan in 2 Hours | Paliperidone ER 9 mg Tablet Followed by PET Scan in 2 Hours | Oral Risperidone 4 mg Tablet Followed by PET Scan in 2 Hours | Oral Risperidone 6 mg Tablet Followed by PET Scan in 2 Hours | Paliperidone ER 6 mg Tablet Followed by PET Scan in 24 Hours | Paliperidone ER 9 mg Tablet Followed by PET Scan in 24 Hours | Oral Risperidone 4 mg Tablet Followed by PET Scan in 24 Hours | Oral Risperidone 6 mg Tablet Followed by PET Scan in 24 Hours | Control | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Germany | — | 1 | — | — | — | — | — | — | 1 | 2 |
The record gives a start of Sep 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Paliperidone · Risperidone